Possibilities of preventive treatment of Alzheimer's disease: Results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 110, Issue 1, 2010, Pages 62-69

  Gavrilova, S I ^a   Kolykhalov, I V ^a   Fedorova, Ya B ^a   Selezneva, N D ^a   Kalyn, Ya B ^a   Roshchina, I F ^a   Odinak, M M ^a   Emelin, A Yu ^a   Kashin, A V ^a   Gustov, A V ^a   Antipenko, E A ^a   Korshunova, Yu A ^a   Davydova, T A ^a   Messler, G ^a  

^a NONE

Author keywords

Alzheimer's disease; Cavinton; Cerebrolysin; Mild cognitive impairment; Preventive treatment

Indexed keywords

CEREBROLYSIN; VINPOCETINE; AMINO ACID; NEUROPROTECTIVE AGENT; VINCA ALKALOID;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PATIENT ASSESSMENT; PROSPECTIVE STUDY; RUSSIAN FEDERATION; UNSPECIFIED SIDE EFFECT; AGED; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SYNDROME; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACIDS; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; SYNDROME; TIME FACTORS; TREATMENT OUTCOME; VINCA ALKALOIDS;

EID: 77954743474     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Alvares X. A., de Olano M., Sampedro C et al. Cerebrolysin protect against neurodegeneration induced by β-amyloid implants in rats. Int J Neuropsychopharmac 2000;3:359.
2. Alvarez X. A., Lombardi V. R., Fernandez-Novoa L. et al. Cerebrolysin reduces microglial activation in-vivo and in-vitro: a potencial mechanism of neuroprotection. J Neurol Transm 2000;59: Suppl: 281-292.
3. Alvares X. A., Cacabelos R., Laredo M. et al. A 24-week, double-blind, placebo-controlled study of dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006;13:43-54.
4. Alzheimer's Association/Every 72 seconds someone in America develops Alzheimer's Chicago: Alzheimer's Association 2007, http://www.alzwa.or/docs// resourses/alzheimers/National Report Facts and Figures.pdf. Accessed May 7, 2007.
5. Chen Y., Tung Yu., Li B. et al. Trophic factor counteract elevated FGF-2 unduced inhibition of adult neurogenesis. Neurobiol Aging 2007;28:1148-1162.
6. Golomb J., Kluger A., Garrard P., Ferris S. Clinician's Manuel on Mild Cognitive Impairment. Science. London: Press Ltd 2001;56.
7. Gschanes A., Windish M. The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neurol Trasmis 1998;53: Suppl: 313-321.
8. Low L. F., Anstey K. J. Dementia literacy: Recognition and Reliegs on Dementia of the Australian public. J Alzheimer's Dementia 2009;5:43-49.
9. Masliah E., Armasolo F., Veinberg I. et al. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behavior 1999;62:239-245.
10. Maslow K. How many people with dementia are hospitalized? In: Improving hospital care for persons with dementia. Eds. N. M. Silvertein, K. Maslow. New York: Springer 2006;3-21.
11. Morris J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
12. Petersen R. C., Smith G. E., Waring S. C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
13. Petersen R. C. Mild cognitive impairment as a diagnostic entity. J Int Med 2004;256:183-194.
14. Reinprecht I., Gschanes A., Windish M., Fachbach G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochemical J 1999;31:395-401.
15. Reisberg B., Ferris S. H., de Leon M. J. et al. The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia. Am J Psychiat 1982;139:1136-1139.
16. Ruther E., Ritter R., Apecechea M. et al. Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with senile dementia of the Alzheimer Type. Pharmacopsychiatry 1994;27:1: 32-40.
17. Sallaw A., Mintzez J., Weiner M., Cummings J. Disease-modifying therapies in Alzheimer's disease. J Alzheimer's Dementia 2008;4:65-79.
18. Windisch M., Gschanes A., Hutter-Paier B. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neurol Transm 1998; Suppl 53:289-298.